510(k) Report

510(k) · Cleared

Cleared

Tidepool Loop

K203689510(k) TraditionalCleared Jan 23, 2023767-day reviewClass II21 CFR 862.1356

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Tidepool Project · QJI Interoperable Automated Glycemic Controller

Cleared on Jan 23, 2023 as substantially equivalent to K200467 (Tandem Diabetes Care, Inc., 2020) after a 767-day review. Its family tree reaches back 2 generations to 2019. 2 later devices descend from it.

Decided
Jan 23, 2023
Review
767 days
Class
Class II
Product code
QJI
Recalls
None
Predicates
1

Its longest line of descent runs back 2 generations to DEN190034 (2019). 2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2024: 1 descendant cleared2025: 1 descendant clearedDEN190034 · Control-IQ Technology · Tandem Diabetes Care, Inc. · 2019K200467 · Control-IQ Technology · Tandem Diabetes Care, Inc. · 2020201620182020202220242026
Descendants, by generation 1 generation forward: 2 descendants K200467 · Control-IQ Technology · Tandem Diabetes Care, Inc. · 2020DEN190034 · Control-IQ Technology · Tandem Diabetes Care, Inc. · 20190
  1. Root · 2 generations backDEN190034 Control-IQ TechnologyTandem Diabetes Care, Inc. · 2019
  2. 1 generation backK200467 Control-IQ TechnologyTandem Diabetes Care, Inc. · 2020
  3. This deviceK203689 Tidepool LoopTidepool Project · 2023
  4. Descendant · cites it directly · 0 of its ownK251152 DBLG2Diabeloop · 2025
  5. Descendant · cites it directly · 0 of its ownK234055 DEKA LoopDeka Research and Development · 2024

Most influential descendants

Showing 2 of 2 · See all
  • K251152DBLG2Diabeloop · 2025 · cites it directly0descendants
  • K234055DEKA LoopDeka Research and Development · 2024 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2DEN190034Control-IQ TechnologyTandem Diabetes Care, Inc.2019—
−1K200467Control-IQ TechnologyTandem Diabetes Care, Inc.2020—
0 (this device)K203689Tidepool LoopTidepool Project2023—
+1K251152DBLG2Diabeloop2025—
+1K234055DEKA LoopDeka Research and Development2024—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202410
202510
FIG. 1 — Lineage of K203689, 2019–2025Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in QJI? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new QJI device

  1. #1 K253701 SmartGuard Technology; Predictive Low Glucose…score 17.1 · 12 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K200467Control-IQ Technology
Summary page 5
…I. Predicate Device Information Device Name Control – IQ Technology Manufacturer: Tandem Diabetes Care, Inc. Premarket Notification #: K200467 Classification Name: Interoperable Automated Glycemic Controller (iAGC) Classification: Class II, 21 CFR 862…
Tandem Diabetes Care, Inc.2020—

Also cleared against K200467: 3 other devices →

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K251152DBLG2Diabeloop20250
K234055DEKA LoopDeka Research and Development20240

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 2.6 years on median.
  • None of the 2 ancestors has a recall.
  • Of its descendants, K251152 (Diabeloop, 2025) has gone furthest, with 0 descendants of its own.
  • 3 other devices also cite its predicate K200467.

How does its category compare?

All QJI devices

QJI Interoperable Automated Glycemic Controller: FDA decisions, review times, recalls and adverse event reports over 20 years. 2023, this device’s year, is highlighted.

FDA decisions per year · QJI

8so far in 2026, the most since 2007

2019: 12020: 12022: 22023: 42024: 42025: 52026 (partial year): 8
2007high 8 (2026) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · QJI

130in 2025

2023: 251 days median2024: 174 days median2025: 130 days median2026 (partial year): 65 days median
2007high 251 (2023) · low 130 (2025)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · QJI

No recall names QJI since 2007.

Adverse event reports per year · QJI

3in 2025

2020: 12021: 12022: 42023: 262024: 152025: 3
2007high 26 (2023) · low 0 (2007)2025

MAUDE reports naming product code QJI, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—00
20080—00
20090—00
20100—00
20110—00
20120—00
20130—00
20140—00
20150—00
20160—00
20170—00
20180—00
20191—00
20201—01
20210—01
20222—04
20234251026
20244174015
2025513003
20268650—

What is it indicated for?

Tidepool Loop, a mobile application with algorithm technology, is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) insulin infusion pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user’s confirmation, control the delivery of correction boluses when glucose values are…

Read the full statement (107 words)

Tidepool Loop, a mobile application with algorithm technology, is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) insulin infusion pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also recommend, and with the user’s confirmation, control the delivery of correction boluses when glucose values are predicted to exceed user configurable thresholds.

Tidepool Loop is intended for the management of type 1 diabetes mellitus in persons six years of age and greater.

Tidepool Loop is intended for single patient use.

Tidepool Loop is Rx - For Prescription Use Only.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K203689: Tidepool Loop.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K203689

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026